Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
1.7100
+0.2400 (16.33%)
NASDAQ · Last Trade: Apr 4th, 7:43 PM EDT
Detailed Quote
Previous Close
1.470
Open
1.820
Bid
1.650
Ask
1.660
Day's Range
1.540 - 1.910
52 Week Range
1.140 - 74.00
Volume
16,002,102
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,563,729
Chart
About Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
Biodexa Pharmaceuticals is a biopharmaceutical company focused on advancing innovative therapies for the treatment of cancer and other serious diseases. The company specializes in developing proprietary drug delivery systems designed to enhance the therapeutic efficacy of existing drugs while minimizing side effects. By leveraging its expertise in nanomedicine and targeted delivery technologies, Biodexa strives to create safer, more effective treatment options to improve patient outcomes in oncology and beyond. Read More
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making progress in readying the launch of a phase 3 trial for eRapa, its proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP).
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP). The news follows Biodexa reporting positive 12-month data from a phase 2 clinical trial in July 2024, as previously covered by Benzinga.
The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer.
